Treatment of Burkitt's Lymphoma in Patients Over 60 Years of Age
Burkitt's lymphoma in older adults requires careful regimen selection. The aggressive nature of the disease calls for prompt, effective treatment, yet the risk of treatment-related mortality rises substantially with age — making the choice of therapy critical in patients over 60.
Clinical Scenario
This protocol applies to patients with Burkitt's lymphoma aged over 60 years. In this population, the effectiveness of intensive therapy must be weighed against the potential for treatment-related mortality, which is notably elevated — estimated at 13% to 17% in patients over 60 — regardless of the specific regimen used.
Treatment Approach
Management in this age group favours a dose-adjusted combination approach chosen for its improved tolerability profile relative to more intensive alternatives. The full regimen, sequencing, and supporting clinical guidance are available in the complete protocol.
References
DOI: 10.1182/blood.2019004099
The effectiveness of intensive therapies for BL must be balanced by the potential for TRM, particularly in older patients or those with underlying comorbidities.
TRM was 13% to 17% in patients >60 years, regardless of treatment regimen.
TRM was higher in patients receiving hyper-CVAD compared with CODOX-M/IVAC or DA-EPOCH-R.
Dose-adjusted R-EPOCH is a generally more tolerable combination, although in patients with baseline CNS disease, the lack of high-dose systemically administered therapy likely contributes to worse outcomes.
View source ↗